{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:42:35Z","timestamp":1790026955016,"version":"4.0.1"},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,4,25]],"date-time":"2014-04-25T00:00:00Z","timestamp":1398384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"crossref","award":["KUN 2010-4820"],"award-info":[{"award-number":["KUN 2010-4820"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contrast Media &amp; Molecular"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:p>D2B is a new monoclonal antibody directed against an extracellular domain of prostate\u2010specific membrane antigen (PSMA), which is overexpressed in prostate cancer. The potential of D2B IgG, and F(ab\u2032)<jats:sub>2<\/jats:sub> and Fab fragments of this antibody for targeting prostate cancer was determined in mice bearing subcutaneous prostate cancer xenografts. The optimal time point for imaging was determined in biodistribution and microSPECT imaging studies with <jats:sup>111<\/jats:sup>In\u2010D2B IgG, <jats:sup>111<\/jats:sup>In\u2010capromab pendetide, <jats:sup>111<\/jats:sup>In\u2010D2B F(ab\u2032)<jats:sub>2<\/jats:sub> and <jats:sup>111<\/jats:sup>In\u2010D2B Fab fragments in mice with PSMA\u2010expressing LNCaP and PSMA\u2010negative PC3 tumors at several time points after injection. All <jats:sup>111<\/jats:sup>In\u2010labeled antibody formats specifically accumulated in the LNCaP tumors, with highest uptake of <jats:sup>111<\/jats:sup>In\u2010D2B IgG and <jats:sup>111<\/jats:sup>In\u2010capromab pendetide at 168\u2009h p.i. (94.8\u2009\u00b1\u200919.2% injected dose per gram (ID\/g) and 16.7\u2009\u00b1\u20092.2% ID\/g, respectively), whereas uptake of <jats:sup>111<\/jats:sup>In\u2010D2B F(ab\u2032)<jats:sub>2<\/jats:sub> and <jats:sup>111<\/jats:sup>In\u2010D2B Fab fragments peaked at 24\u2009h p.i. (12.1\u2009\u00b1\u20093.0% ID\/g and 15.1\u2009\u00b1\u20092.9% ID\/g, respectively). Maximum LNCaP tumor\u2010to\u2010blood ratios were 13.0\u2009\u00b1\u20092.3 (168\u2009h p.i.), 6.2\u2009\u00b1\u20090.7 (24\u2009h p.i.), 23.0\u2009\u00b1\u20094.0 (24\u2009h p.i.) and 4.5\u2009\u00b1\u20090.6 (168\u2009h p.i.) for <jats:sup>111<\/jats:sup>In\u2010D2B IgG, <jats:sup>111<\/jats:sup>In\u2010F(ab\u2032)<jats:sub>2<\/jats:sub>, <jats:sup>111<\/jats:sup>In\u2010Fab and <jats:sup>111<\/jats:sup>In\u2010capromab pendetide, respectively. LNCaP tumors were clearly visualized with microSPECT with all antibody formats. This study demonstrates the feasibility of D2B IgG, F(ab\u2032)<jats:sub>2<\/jats:sub> and Fab fragments for targeting PSMA\u2010expressing prostate cancer xenografts. Copyright \u00a9 2014 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/cmmi.1596","type":"journal-article","created":{"date-parts":[[2014,4,25]],"date-time":"2014-04-25T08:57:28Z","timestamp":1398416248000},"page":"28-36","source":"Crossref","is-referenced-by-count":31,"title":["Targeting human prostate cancer with <sup>111<\/sup>In\u2010labeled D2B IgG, F(ab\u2032)<sub>2<\/sub> and Fab fragments in nude mice with PSMA\u2010expressing xenografts"],"prefix":"10.1002","volume":"10","author":[{"given":"Susanne","family":"L\u00fctje","sequence":"first","affiliation":[{"name":"Department of Radiology and Nuclear Medicine Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina M.","family":"van Rij","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerben M.","family":"Franssen","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Fracasso","sequence":"additional","affiliation":[{"name":"Department of Pathology and Diagnostics University of Verona  Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wijnand","family":"Helfrich","sequence":"additional","affiliation":[{"name":"Department of Surgery University Medical Center Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Eek","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim J.","family":"Oyen","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Colombatti","sequence":"additional","affiliation":[{"name":"Department of Pathology and Diagnostics University of Verona  Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto C.","family":"Boerman","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.09.046"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.047787"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2005.09.001"},{"issue":"2","key":"e_1_2_8_5_1","first-page":"227","article-title":"Molecular cloning of a complementary DNA encoding a prostate specific membrane antigen","volume":"53","author":"Israeli RS","year":"1993","journal-title":"Cancer Res"},{"issue":"17","key":"e_1_2_8_6_1","first-page":"6357","article-title":"Correlation of primary tumor prostate\u2010specific membrane antigen expression with disease recurrence in prostate cancer","volume":"9","author":"Ross JS","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"5","key":"e_1_2_8_7_1","first-page":"927","article-title":"Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients","volume":"7","author":"Horoszewicz JS","year":"1987","journal-title":"Anticancer Res"},{"key":"e_1_2_8_8_1","unstructured":"FDA.Capromab pendetide product approval information. Available from:http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/ucm080734.htm"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19970101)30:1<65::AID-PROS10>3.0.CO;2-N"},{"issue":"18","key":"e_1_2_8_10_1","first-page":"5237","article-title":"In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate\u2010specific membrane antigen","volume":"60","author":"Smith\u2010Jones PM","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.154"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000091655.77601.0c"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.160"},{"key":"e_1_2_8_14_1","unstructured":"ColombattiM.Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen conjugates and uses thereof. WO 2009\/130575 A2 International Patent Application (PCT\/IB2009\/005326)."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0483"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(82)90137-5"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(84)90435-6"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.075648"},{"issue":"3","key":"e_1_2_8_19_1","first-page":"814s","article-title":"Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors","volume":"50","author":"Jain RK","year":"1990","journal-title":"Cancer Res"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.20652"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.081626898"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp300232n"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/1078-1439(95)00004-2"}],"container-title":["Contrast Media &amp; Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcmmi.1596","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cmmi.1596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T15:15:48Z","timestamp":1696605348000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cmmi.1596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,25]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1002\/cmmi.1596"],"URL":"https:\/\/doi.org\/10.1002\/cmmi.1596","archive":["Portico"],"relation":{},"ISSN":["1555-4309","1555-4317"],"issn-type":[{"value":"1555-4309","type":"print"},{"value":"1555-4317","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,25]]}}}